After five years, a higher proportion of the participating men in the active surveillance group (68%) were found to experience a disease progression event compared with the VTP-treated patients (38%).
The median time to disease progression of 13.8 months among men in the active surveillance arm, but in the VTM arm, there is still has not been a period reached.